Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus investigator's choice chemotherapy in platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck
NL-OMON44380Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival and Overall survival. Started Jul 2014; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON44380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44380.